Ortek's Electronic Device to Detect the Earliest Signs of Dental Cavities Awarded a U.S. Patent

ROSLYN HEIGHTS, N.Y., March 16, 2016 /PRNewswire/ -- Ortek Therapeutics, Inc., a global leader in oral care innovations and microbiome technology, announced today that a U.S. Patent has been recently awarded for the Ortek ECD™ (ECD) dental device, a system for detecting early or pre-cavity lesions that cannot be readily detected by visual examination or x-ray. Human and laboratory clinical studies have demonstrated that the ECD device can detect the earliest stages of tooth demineralization or pre-cavity lesions with 100% accuracy. 

Except for the common cold, tooth decay is the most prevalent disease globally. Approximately 5 billion people suffer from dental cavities throughout the world, including 60–90% of school-age children.

The ECD device is designed to detect pre-cavity lesions in molars and premolars, the back teeth with the highest rates of decay. The biting surfaces of these teeth have deep grooves that often retain acid-producing bacteria. Over time, acid attacks can lead to tooth mineral loss, which initiates the development of cavities.

Tooth enamel is electrically non-conductive unless breached by demineralization or fracture. When this occurs, dentinal fluid percolates through the breached enamel site and enables the battery-powered ECD to complete its electrical circuit.

The ECD device features a handpiece with a probe tip and can precisely measure the amount of dentinal fluid seepage. The more fluid it detects, the greater the extent of the pre-cavity lesion. This data enables the dental practitioner to determine the severity of any lesions and design an appropriate treatment plan that could include minimally invasive care.

"We believe the ECD is a major breakthrough in oral care," said Mitchell Goldberg, President of Ortek Therapeutics Inc. "Dental professionals will soon have a new and valuable tool that will help their patients avoid cavities. We are now evaluating commercialization strategies and are pursuing U.S. FDA and worldwide marketing clearances."

U.S. Patent 9,277,875, "Device for the Detection of Non-Cavitated Early Dental Caries Lesions" was issued to The Research Foundation for the State University of New York (Albany, NY). Its revolutionary technology was developed at Stony Brook University School of Dental Medicine.

Ortek has exclusive worldwide licensing rights to this patented technology. Patents covering this device have also been issued in Australia, China and Mexico with other patents pending worldwide.

About Ortek Therapeutics

Ortek Therapeutics, Inc. is a global leader in developing cutting-edge oral care innovations. Through a strategic alliance with The Research Foundation of State University of New York, Ortek has developed major scientific breakthroughs in oral and cutaneous microbiome technology. The company has developed and commercialized revolutionary technology for dental cavity prevention, detection, and treatments for dentinal sensitivity. The Company's core oral microbiome AlkaGen Technology®, which is contained in its proprietary BasicBites® soft chew confections, is based on the scientific expertise of researchers in the Department of Oral Biology and Pathology at Stony Brook University School of Dental Medicine.

SOURCE Ortek Therapeutics, Inc.

Related Links

http://www.ortekinc.com